Immunodiagnostic Systems Holdings plc.
19 October 2016
Launch of IDS-iSYS Total Testosterone assay - new assay in the IDS fertility portfolio
Immunodiagnostic Systems Holdings plc (IDS), a specialist producer of manual and automated diagnostic testing kits and instruments for the clinical market, has launched the IDS-iSYS Total Testosterone assay in the European market. This is a fully automated CLIA assay for use with serum and plasma samples on the IDS-iSYS Automated System.
The launch of the IDS-iSYS Total Testosterone assay is the second product released as part of the emerging fertility (steroid hormones) portfolio following the launch of the IDS-iSYS 17-OH Progesterone assay in May 2016.
The IDS-iSYS Total Testosterone assay quantitatively measures a patient's Testosterone level and offers clinicians an easy, non-invasive way to diagnose and treat disorders involving the male sex hormones (androgens).
The global market for testosterone tests has been valued at around $110 million per year.
For further information:
Immunodiagnostic Systems Holdings plc Tel: +44 (0) 191 519 0660
Patricio Lacalle, Chief Executive Officer
Paul Martin, Group Finance Director
Peel Hunt LLP Tel: +44 (0) 20 7418 8900
This information is provided by RNS